Where Is Russia’s Strongman in the Coronavirus Crisis?
Putin Lets Local Leaders Take the Credit and the Fall
The rush is on to come up with a viable vaccine against COVID-19, the disease caused by the new coronavirus. Scores of academic institutions and companies around the world are hard at work, and at least eight vaccine candidates have reached or are approaching the clinical trial stage. Oxford University’s Jenner Institute is currently leading the race and due to start large-scale human trials by the end of May. This week, a Massachusetts-based biotech firm, Moderna, announced that its coronavirus vaccine had safely produced protective antibodies in human volunteers in early-stage testing.
A similar push is on to develop antiviral drugs and other therapeutics—and to repurpose existing ones—to treat those infected with the coronavirus. By mid-April, in the United States alone, 950 drug development proposals had been submitted to the Food and Drug Administration for approval, and more than 70 COVID-19 medication trials were underway. The pace is remarkable:
The Pandemic Is Exposing Market Vulnerabilities No One Knew Existed